Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS

GOSS Investors with Losses Encouraged to Contact the Firm Before June 1st Deadline SAN FRANCISCO, May 23, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or...